Tocilizumab (Actemra, intravenous) : for the treatment of signs and symptoms of active polyarticular juvenile idiopathic arthritis in patients two years of age and older who have responded inadequately to previous therapy with disease-modifying antirheumatic drugs and systemic corticosteroids

The objective of this systematic review is to examine the beneficial and harmful effects of IV tocilizumab in the treatment of active polyarticular juvenile idiopathic arthritis (pJIA)

Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2014, [2014]
Series:Common drug review
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Summary:The objective of this systematic review is to examine the beneficial and harmful effects of IV tocilizumab in the treatment of active polyarticular juvenile idiopathic arthritis (pJIA)
Item Description:Title from PDF caption. - "August 2014."
Physical Description:1 PDF file (vii, 65 pages) illustrations